Policy Developments - The National Medical Products Administration (NMPA) held a meeting to promote the boron neutron capture therapy system, emphasizing the need for enhanced coordination in drug and device reviews to accelerate the deployment of advanced medical equipment for cancer treatment [2] Drug and Device Approvals - Kehua Bio announced that its subsidiaries received medical device registration certificates for various in vitro diagnostic reagents, which will enrich the company's product line and positively impact business development, although future revenue impact remains uncertain [4] - Heng Rui Medicine reported that its subsidiaries received clinical trial approval notices for SHR-7787 injection and Abedolizumab injection, with plans to conduct clinical trials soon [5] Capital Market Activities - Hite Bio plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its competitiveness and utilize international capital markets for diversified financing [7] - Hualan Biological announced a 450 million RMB capital increase for its wholly-owned subsidiary, Lingqing Intelligent, to strengthen its capabilities in AI drug development and commercialization [8] - Aibo Medical intends to acquire at least 51% of Demai Medical's shares to gain control, aiming to expand into the sports medicine sector [9][10] Industry Events - The fourth batch of traditional Chinese medicine centralized procurement is expected to progress, with significant price reductions observed in previous batches, indicating a shift in the competitive landscape of the industry [12] - Junshi Bioscience established a new technology company in Shanghai with a registered capital of 500 million RMB, focusing on various consulting and import-export services [13] Shareholder Movements - Jiukang Bio reported that a shareholder reduced their holdings by 1.4543 million shares, representing 0.248% of the total share capital, during a period when the stock price increased by 1.95% [15]

Group 1 - The core point of the article is that Hite Bio (300683) reported a total of 19,743 shareholders as of January 20, 2026 [1]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

武汉海特生物制药股份有限公司 关于召开2026年第一次临时股东会的通知 证券代码：300683 证券简称：海特生物 公告编号：2026-009 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）拟于 2026 年 2 月 5 日（星期四）14：30 召开 2026 年第一次临时股东会。现将本次股东会的相关事 项通知如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、会议召集人：公司董事会 3、会议召开的合法性及合规性：公司第九届董事会第七次会议审议通过了 《关于提请召开 2026 年第一次临时股东会的议案》，本次股东会的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2026 年 2 月 5 日（星期四）14:30。 （2）网络投票时间：2026 年 2 月 5 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 2 月 5 日的交易时间，即 9:15-9:25，9:30-11:30 ...

证券代码：300683 证券简称：海特生物 公告编号：2026-008 武汉海特生物制药股份有限公司 关于召开2026年第一次临时股东会通知的更正公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）于 2026 年 1 月 20 日披露了《关于召开 2026 年第一次临时股东会的通知》。经核查发现附件"二 授 权委托书"中的个别子议案有遗漏，现更正如下： 更正前： 附件 2 授权委托书 武汉海特生物制药股份有限公司董事会： 附件 2 授权委托书 武汉海特生物制药股份有限公司董事会： 兹全权委托 先生/女士代表本人/本公司出席武汉海特生物制药股份 有限公司 2026 年 2 月 5 日召开的 2026 年第一次临时股东会，并代表本人/本公 司行使表决权。如委托人未对表决权做明确具体的指示，则视为受托人有权按照 自己的意愿进行表决，其行使表决权的后果均为本人/本公司承担。 委托人对下列议案表决如下（请在相应表决意见项划"√"，以明确表示同 意、反对、弃权）： 兹全权委托 先生/女士代表本人/本公司出席武汉海特生物制 ...

本次发行上市还需经股东会审议，并需取得中国证监会、香港联交所和香港证券及期货事务监察委员会 等相关监管机构备案、批准和/或核准。市场有风险，投资需谨慎，本文内容仅供参考，具体以公司公 告为准。 （海特生物公告） (编辑：杨燕 林辰) 近日，海特生物发布公告称，公司董事会审议通过发行H股并在香港联交所主板上市的相关议案。 公告称，此举旨在提升公司综合竞争力与国际品牌形象，利用国际资本市场，拓宽融资渠道。目前，公 司正与相关中介机构就发行上市工作进行商讨，具体发行股份比例等细节尚未确定。 ...

格隆汇1月20日丨海特生物(300683.SZ)公布，公司于2026年1月20日召开第九届董事会第七次会议，会 议审议通过了《关于聘任公司高级管理人员的议案》，因公司经营管理需要，根据《公司法》《深圳证 券交易所创业板股票上市规则》及《公司章程》等相关规定，经公司总经理陈亚先生提名，董事会提名 委员会审核，聘任汤华东先生、赵满岐先生为公司副总经理，任期自本次董事会审议通过之日起至第九 届董事会任期届满之日止。 ...

Key Highlights - Daying Electronics reported current revenue from its unmanned robot business [1] - Hite Bio is planning to issue H-shares and list on the Hong Kong Stock Exchange [1] - Huangshan Tourism is investing approximately 133 million yuan in the upgrade of the Huangshan Tai Ping cableway electrical system [1] - Huatai Technology signed a daily operation contract worth 328 million yuan [1] - Tonghuashun expects a net profit growth of 50%-80% year-on-year for 2025 [1] - Kangxin New Materials plans to acquire 51% equity in Zibang Semiconductor for 392 million yuan [1] - Hengtong Co. intends to repurchase shares worth between 80 million to 100 million yuan [1] - Lanyu Co. shareholders Wang Yinghai and Yushuo Investment plan to reduce their holdings by up to 3% [1][2] - Jinma Amusement plans to raise no more than 1.05 billion yuan through a private placement [2] - Jincai Interconnection plans to raise no more than 570 million yuan through a private placement [2] Investment Projects - Kaizhong Precision plans to upgrade and expand its manufacturing base for new energy vehicle components in Heyuan [1] - Jiangtian Chemical intends to invest in a project with an annual production capacity of 60,000 tons of acrylic acid [1] - Nanjing Julong plans to establish a wholly-owned subsidiary to invest in a modified plastic production line project [1] Performance Forecasts - Batian Co. expects a net profit growth of 117.53% to 139.53% year-on-year for 2025 [1] - Tongfu Microelectronics anticipates a net profit of 1.1 billion to 1.35 billion yuan for 2025, representing a year-on-year growth of 62.34% to 99.24% [1] - Putailai expects a year-on-year increase in net profit of 93.18% to 101.58% for the 2025 fiscal year [1]

海特生物（300683）(300683.SZ)公告，公司拟发行境外上市外资股(H股)股票并申请在中国香港联交所 主板挂牌上市。 ...

智通财经APP讯，海特生物(300683.SZ)公告，公司拟发行境外上市外资股(H股)股票并申请在中国香港 联交所主板挂牌上市。 ...